Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Phase II and phase III failures: 2013–2015

Nature Reviews Drug Discovery volume 15, pages 817–818 (2016)Cite this article

Subjects

During this time period, there were 218 reported failures between phase II (including phase I/II) and submission (each drug indication combination is considered as a separate record and both new active substances and new indications of marketed drugs are included in the analysis). Of these failures, 174 had stated the reason for the failure and these were used in the subsequent analysis.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Reasons for clinical trial failures 2013–2015.
Figure 2: Recent trends in clinical trial failures.

Author information

Authors and Affiliations

  1. Richard K. Harrison is the Chief Scientific Officer at Clarivate Analytics, 1500 Spring Garden Street, Philadelphia, Pennsylvania 19103, USA.,

    Richard K. Harrison

Authors
  1. Richard K. Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard K. Harrison.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Related links

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Harrison, R. Phase II and phase III failures: 2013–2015. Nat Rev Drug Discov 15, 817–818 (2016). https://doi.org/10.1038/nrd.2016.184

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2016.184

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research